Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Natera, Inc. before investing.

In this article, we go over a few key elements for understanding Natera, Inc.’s stock price such as:

• Natera, Inc.’s current stock price and volume
• Why Natera, Inc.’s stock price changed recently
• Upgrades and downgrades for NTRA from analysts
• NTRA’s stock price momentum as measured by its relative strength

About Natera, Inc. (NTRA)

Before we jump into Natera, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Want to learn more about Natera, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Natera, Inc..

Natera, Inc.’s Stock Price as of Market Close

As of May 08, 2026, 10:48 AM, CST, Natera, Inc.’s stock price was $205.070.

Natera, Inc. is down 6.71% from its previous closing price of $219.820.

During the last market session, Natera, Inc.’s stock traded between $198.500 and $217.650. Currently, there are approximately 138.34 million shares outstanding for Natera, Inc..

Natera, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Natera, Inc. Stock Price History

Natera, Inc.’s (NTRA) price is currently down 0.53% so far this month.

During the month of May, Natera, Inc.’s stock price has reached a high of $221.560 and a low of $198.500.

Over the last year, Natera, Inc. has hit prices as high as $256.360 and as low as $131.811. Year to date, Natera, Inc.’s stock is down 10.48%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Natera, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there was 1 analyst who downgraded Natera, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Natera, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Natera, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Natera, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Natera, Inc. (NTRA) by visiting AAII Stock Evaluator.

Relative Price Strength of Natera, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, Natera, Inc. has a weighted four-quarter relative price strength of 2.90%, which translates to a Momentum Score of 67 and is considered to be Strong.

Want to learn more about how Natera, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Natera, Inc. Stock Price: Bottom Line

As of May 8, 2026, Natera, Inc.’s stock price is $205.070, which is down 6.71% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Natera, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.